uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
Go back to uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B| CARLISLE COMPANIES, Inc. (NYSE: CSL) | Delayed: 352.88 -8.08 (2.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $360.96 | 52 Week High | $114.49 | |||
| Open | $354.76 | 52 Week Low | $75.17 | |||
| Day High | $358.75 | P/E | 97.75 | |||
| Day Low | $351.21 | EPS | $3.61 | |||
| Volume | 292,152 | |||||
| (AMEX: CSLLY) | Delayed: 19.59 -0.29 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.88 | 52 Week High | $45.60 | |||
| Open | $19.50 | 52 Week Low | $33.39 | |||
| Day High | $19.73 | P/E | N/A | |||
| Day Low | $19.44 | EPS | $0.00 | |||
| Volume | 907,368 | |||||
| UNIQURE (NASDAQ: QURE) | Delayed: 49.04 +4.65 (10.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.39 | 52 Week High | $22.79 | |||
| Open | $44.47 | 52 Week Low | $6.63 | |||
| Day High | $49.58 | P/E | N/A | |||
| Day Low | $44.47 | EPS | $0.00 | |||
| Volume | 3,439,189 | |||||
